Floatz logo

Idarubicine

Safety

Shanghai General Hospital, Shanghai Jiao Tong University School of MedicinePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

30 Active assets in the Safety cohort.

Asset / SponsorPhaseRating
Bortezomib
Shandong Provincial Hospital
Phase 4BB
Gemtuzumab Ozogamicin
Pfizer
Phase 4BB
Inno-206
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4B
DEXAMETHASONE
Shandong Provincial Hospital
Phase 4B
gv-971
First Affiliated Hospital Xi'an Jiaotong University
Phase 4B

View all 48 →

Same molecule, other indications

Idarubicine is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
81 / 100
View asset →
Acute Promyelocytic LeukemiaDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →